NDAORALTABLET
Approved
Oct 1956
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 1h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
MODERIL (rescinnamine) is an oral small-molecule antihypertensive agent approved in 1956 by Pfizer. It is an alkaloid derivative indicated for blood pressure management. The mechanism of action involves sympathomimetic inhibition, reducing catecholamine release.
LOE Approaching
Product approaching loss of exclusivity with minimal commercial momentum; brand team likely operating in maintenance mode with small headcount.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on MODERIL offers limited career momentum; roles focus on legacy portfolio management, compliance, and gradual wind-down rather than growth or innovation. This assignment is best suited for professionals gaining experience in mature/declining asset stewardship or transition planning.
Brand Manager (Specialty/Legacy)Commercial Operations Analyst
Worked on MODERIL at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.